Recent advances in the treatment of acquired hemophilia A.

Corresponding author: LI Chengping

DOI: 10.12201/bmr.202505.00006

•  

  Abstract: Acquired Hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies against coagulation FⅧ in the bloodstream, leading to decreased coagulation FⅧ activity. AHA occurs in all age groups, but it is most commonly seen in the elderly and postpartum women. Clinically, it is characterized by spontaneous bleeding or severe bleeding following trauma. The treatment for AHA focuses on obtaining a rapid and accurate diagnosis and implementing timely therapeutic measures. Treatment involves managing acute bleeding, removing inhibitors, and aggressively addressing the primary disease. To control bleeding, alternative therapies such as recombinant porcine FⅧ, desmopressin (DDAVP), and emicizumab can be used, along with bypass pathway drugs. The removal of inhibitors mainly depends on immunosuppressive therapies, including first- and second-line treatment options. In recent years, newer therapies such as CD38 monoclonal antibodies and the CyDRi regimen (cyclophosphamide, dexamethasone, and rituximab) have demonstrated promising efficacy and safety profiles. These treatments offer new options for patients with AHA.

  Key words: Acquired hemophilia A; Coagulation factor Ⅷ; Treatment；Hemorrhagic disorder; 

  Submit time: 10 May 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• liangjuanfang. A Study on Health Needs of Patients with Rare Diseases Based on LDA: A Case Study of Hemophilia.. 2025. doi: 10.12201/bmr.202509.00066

  肖岑昕, HUANG Xuri, ZHAO Weidan. The correlation assessment of serum iron in the identification of community-acquired pneumonia in middle-aged and elderly individuals. 2025. doi: 10.12201/bmr.202501.00002

  WU Xiayang. The mechanisms of action of SGLT2i in the treatment of heart failure and recent research advances. 2025. doi: 10.12201/bmr.202507.00052

  guolianmei, sunxiaohong, zhangzhe, tianye. Construction of a Prediction Model for Lower Limb Deep Vein Thrombosis in Patients with Hemorrhagic Stroke Based on Machine Learning. 2025. doi: 10.12201/bmr.202510.00023

  ZHANG Xiao-Hua, YANG Yi-Tong. Progress of community-acquired respiratory distress syndrome toxins in Mycoplasma pneumoniae infection in children. 2025. doi: 10.12201/bmr.202506.00057

  任前军, Lisu, Chenyuqing, luweiqing, mengxiaozu, Zhaoxiaofang, Liuxudong. Research Progress of Granulocyte Colony Stimulating Factor in the Treatment of Liver Failure. 2025. doi: 10.12201/bmr.202505.00003

  XuHong. Advances in the treatment of osteopenia-seropathic obesity syndrome in the elderly. 2024. doi: 10.12201/bmr.202411.00064

  Yu Liu, Yalong Dang. New progress of drug intervention for prevention and control of myopia. 2022. doi: 10.12201/bmr.202210.00012

  张亚, HE kai. . 2025. doi: 10.12201/bmr.202510.00016

  Yang min. Study on the Treatment of Coagulation Dysfunction and Limb Swelling after Bloodborne Venom Snake Bite with Hyperbaric Oxygen Combined with External Use of Snake Damage Powder. 2024. doi: 10.12201/bmr.202407.00060

• ID	Submit time	Number	Download
  1	2025-03-09	10.12201/bmr.202505.00006V1	Download

• Public  Anonymous  To author only Submit Comments